Hereditary Cancer Syndrome
A hereditary cancer syndrome is a genetic disorder in which inherited mutations in various genes predispose individuals to the development of cancers such as breast, ovarian, colorectal, endometrial, gastric, prostate, pancreatic cancers, and melanoma. These form approximately 5 to 10 percent of all cancers. Currently genetic mutations associated with over 50 hereditary cancer syndromes have been classified and family members harboring these changes can be identified through genetic testing.
Most cancer syndromes are inherited through autosomal dominant pattern. The mutated gene is a dominant gene located on one of the non-sex chromosomes (autosomes). Only one mutated (affected) gene is needed for manifestation of symptoms.
Early identification of affected individuals through appropriate testing can lead to appropriate surveillance measures, early diagnosis, and improved treatment options, thus improving patient outcome as a whole. In addition, it serves to motivate other individuals of the same family to undergo genetic testing if affected individual is a primary case.
The Myriad myRisk™ Hereditary Cancer test is a scientific advancement revolutionizing hereditary cancer testing.
Personalized Cancer Therapy Test Panels
CANCERSELECT™ utilizes a 88 cancer gene panel for the detection of genetic alterations in well-characterized cancer genes, having either approved-therapies or active clinical trials. These genes are of clinical and biologic importance and are screened using next generation sequencing at high coverage (>500x) to identify point mutations, copy number alterations, and rearrangements.
CANCERCOMPLETE™ is a more comprehensive test that looks at 20,766 genes in the cancer cells.